Novo Nordisk will invest $506 million to expand the Ireland factory

2026-03-02 19:14:38

Abstract generation in progress

Investing.com – Novo Nordisk (CSE:NOVOb) announced on Monday that it will invest €432 million ($506.43 million) to expand its manufacturing facility in Aslone, Ireland.

Kasper Bodker Mejlvang, Head of Product Supply at Novo Nordisk, stated in a release that this investment will increase the production capacity of oral products and enhance the company’s ability to meet current and future demand outside the United States.

The company said the expansion will improve Novo Nordisk’s ability to produce its oral GLP-1 medications, including Wegovy and Ozempic.

Novo Nordisk stated that the construction project has already begun and is expected to be completed gradually from the end of 2027 to 2028.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.